Previous 10 | Next 10 |
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler J...
Supernus Pharmaceuticals press release (NASDAQ:SUPN): Q1 GAAP EPS of $0.43 misses by $0.02. Revenue of $152.51M (+16.5% Y/Y) beats by $2.04M. Non-GAAP operating income of $28.0 million. U.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adults. Qelbree&...
First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021 First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively First quarter 2022 GAAP operating income of $2.0 million; first ...
Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is $0.45 (+225.0% Y/Y) and the consensus Revenue Estimate is $150.47M (+679.2% Y/Y). Over the last 1 year, SUPN has beaten EPS estimates 75% o...
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report finan...
Supernus Pharmaceuticals (NASDAQ:SUPN), a pharma company focused on CNS disorders, is trading ~9% higher in the pre-market Monday after the firm announced that the U.S. Food and Drug Administration (FDA) expanded the indication for its ADHD therapy Qelbree. Accordingly, the drug, al...
First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on de...
Supernus Pharmaceuticals press release (NASDAQ:SUPN): Q4 GAAP EPS of $0.04 misses by $0.20. Revenue of $159.05M (+10.8% Y/Y) in-line. 2022 Guidance: Total revenues $640 - $680M, Combined R&D and SG&A expenses $460 - $490M, Operating earnings $20 - $40M, Effective tax rate 25% - 2...
Annual Report on Form 10-K filed on April 13, 2022 Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022 ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutica...
Biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases Supernus Pharmaceuticals (NASDAQ:SUPN) reiterates FY2022 financial guidance initially announced on February 28, 2022. Expects total revenues between $640...
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...
2024-05-24 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...